Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 3/2017

01.03.2017 | Neurotrauma (M Kumar, Section Editor)

The Application of Proteomics to Traumatic Brain and Spinal Cord Injuries

verfasst von: George Anis Sarkis, Manasi D. Mangaonkar, Ahmed Moghieb, Brian Lelling, Michael Guertin, Hamad Yadikar, Zhihui Yang, Firas Kobeissy, Kevin K. W. Wang

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Traumatic brain injury (TBI) and traumatic spinal cord injury (SCI), collectively termed neurotrauma, are two parallel neurological conditions that can cause long-lasting neurological impairment and other comorbidities in patients, while at the same time, can create a high burden to society. To date, there are still no FDA-approved therapeutic interventions for either TBI or SCI. Recent advances in proteomic technologies, including tandem mass spectrometry, as well as imaging mass spectrometry, have enabled new approaches to study the differential proteome in TBI and SCI with the use of either animal disease models and/or biosamples from clinical observational studies. Thus, the applications of state-of-the-art proteomic method hold promises in shedding light on identifying clinically useful neurotrauma “biomarkers” and/or in identifying distinct and, otherwise, unobvious systems pathways or “key drivers” that can be further exploited as new therapeutic intervention targets.
Literatur
1.
Coles JP, Fryer TD, Smielewski P, Chatfield DA, Steiner LA, Johnston AJ, et al. Incidence and mechanisms of cerebral ischemia in early clinical head injury. J Cereb Blood Flow Metab. 2004;24:202–11.CrossRefPubMed
2.
Menon DK, Coles JP, Gupta AK, Fryer TD, Smielewski P, Chatfield DA, et al. Diffusion limited oxygen delivery following head injury. Crit Care Med. 2004;32(6):1384–90.CrossRefPubMed
3.
Lakshmanan R, Loo JA, Drake T, Leblanc J, Ytterberg AJ, Mcarthur DL, et al. Metabolic crisis after traumatic brain injury is associated with a novel microdialysis proteome. Neurocrit Care. 2010;12(3):324–36.CrossRefPubMedPubMedCentral
4.
Timofeev I, Carpenter KLH, Nortje J, Al-Rawi PG, O’connell MT, Czosnyka M, et al. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. Brain. 2011;134(2):484–94.CrossRefPubMed
5.
Zhang P, Zhu S, Li Y, Zhao M, Liu M, Gao J et al. Quantitative proteomics analysis to identify diffuse axonal injury biomarkers in rats using iTRAQ coupled LC–MS/MS. J Proteomics. 2016;133:93–9.
6.
Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun. 2012;26(8):1191–201.CrossRefPubMed
7.
Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 2004;14(2):215–22.CrossRefPubMed
8.
• Chauhan NB. Chronic neurodegenerative consequences of traumatic brain injury. Restor Neurol Neurosci. 2014;32:337–65. Chauhan studied the consequences of traumatic brain injuries and its wide-ranging possibilities of affecting people’s lives. He studied common and deadly diseases such as Alzheimer’s and its relationship to TBI and repeated TBI can lead to chronic traumatic encephalopathy (CTE).PubMed
9.
Rao VLR, Dhodda VK, Song G, Bowen KK, Dempsey RJ. Traumatic brain injury-induced acute gene expression changes in rat cerebral cortex identified by GeneChip analysis. J Neurosci Res. 2003;71(2):208–19.CrossRef
10.
Wang KKW. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23(1):20–6.CrossRefPubMed
11.
Ansari MA, Roberts KN, Scheff SW. Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury. Free Radic Biol Med. 2008;45(4):443–52.CrossRefPubMedPubMedCentral
12.
Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McIntosh TK. Protein accumulation in traumatic brain injury. Neuromolecular Med. 2003;4:59–72.CrossRefPubMed
13.
Zhang X, Chen Y, Ikonomovic MD, Nathaniel PD, Kochanek PM, Marion DW, et al. Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats. J Cereb Blood Flow Metab. 2005;26(7):915–26.CrossRefPubMed
14.
Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–74.CrossRefPubMedPubMedCentral
15.
16.
Hook G, Jacobsen JS, Grabstein K, Kindy M, Hook V. Cathepsin B is a new drug target for traumatic brain injury therapeutics: evidence for E64d as a promising lead drug candidate. Front Neurol. 2015;6.
17.
Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States emergency department visits, hospitalizations and deaths 2002–2006. 2010;1–74.
18.
•• Ordikhani F, Sheth S, Zustiak SP. Polymeric particle-mediated molecular therapies to treat spinal cord injury. Int J Pharm. 2016;16(31073):S0378–5173. Ordikhani et al. recognizes the issues that affect those that suffer from SCI. They review the benefits and challenges that polymeric particles can take on as a potential therapeutic help to those needing SCI treatment.
19.
National Center for Injury Prevention and Control. Report to congress on mild traumatic brain injury in the united states: steps to prevent a serious public health problem. 2003;1–45.
20.
Yamasaki K, Setoguchi T, Takenouchi T, Yone K, Komiya S. Stem cell factor prevents neuronal cell apoptosis after acute spinal cord injury. Spine. 2009;34(4):323–7.CrossRefPubMed
21.
Chen M, Xia X, Zhu X, Cao J, Xu D, Ni Y, et al. Expression of SGTA correlates with neuronal apoptosis and reactive gliosis after spinal cord injury. Cell Tissue Res. 2014;358(2):277–88.CrossRefPubMed
22.
Ellis RC, Earnhardt JN, Hayes RL, Wang KK, Anderson DK. Cathepsin B mRNA and protein expression following contusion spinal cord injury in rats. J Neurochem. 2004;88(3):689–97.CrossRefPubMed
23.
Ellis RC, O’steen WA, Hayes RL, Nick HS, Wang KK, Anderson DK. Cellular localization and enzymatic activity of cathepsin B after spinal cord injury in the rat. Exp Neurol. 2005;193(1):19–28.CrossRefPubMed
24.
Zhang H, Chu G, Pan C, Hu J, Guo C, Liu J, et al. A nutrient mixture reduces the expression of matrix metalloproteinases in an animal model of spinal cord injury by modulating matrix metalloproteinase-2 and matrix metalloproteinase-9 promoter activities. Exp Ther Med. 2014;8(6):1835–40.PubMedPubMedCentral
25.
26.
Hoffman SW, Harrison C. The interaction between psychological health and traumatic brain injury: a neuroscience perspective. Clin Neuropsychol. 2009;23(8):1400–15.CrossRefPubMed
27.
Papurica M, Rogobete AF, Sandesc D, Dumache R, Cradigati CA, Sarandan M, et al. Advances in biomarkers in critical ill polytrauma patients. Clin Lab. 2016;62(6):977–86.PubMed
28.
Stammers A, Liu J, Kwon B. Expression of inflammatory cytokines following acute spinal cord injury in a rodent model. J Neurosci Res. 2012;90(4):782–90.CrossRefPubMed
29.
Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma. 2010;27(4):669–82.CrossRefPubMed
30.
Kwon BK, Casha S, Hurlbert RJ, Yong VW. Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin Chem Lab Med. 2011;49(3):425–33.CrossRefPubMed
31.
Springer JE, Azbill RD, Kennedy SE, George J, Geddes JW. Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment. J Neurochem. 1997;69(4):1592–600.CrossRefPubMed
32.
Zhang SX, Underwood M, Landfield A, Huang F-F, Gibson S, Geddes JW. Cytoskeletal disruption following contusion injury to the rat spinal cord. J Neuropathol Exp Neurol. 2000;59(4):287–96.CrossRefPubMed
33.
Hanrieder J, Wetterhall M, Enblad P, Hillered L, Bergquist J. Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J Neurosci Methods. 2009;177(2):469–78.CrossRefPubMed
34.
•• Xu B, Tian R, Wang X, Zhan S, Wang R, Guo Y, et al. Protein profile changes in the frontotemporal lobes in human severe traumatic brain injury. Brain Res. 2016;1642:344–52. Xu et al. utilized bioinformatics analysis to relate the effects of severe traumatic brain injury with alterations in biological pathways in the brain. They observed through both mass spectrometry and western blot techniques the increased levels of GFAP, MMP9, transgelin, and vimentin in people suffering from severe TBI (sTBI).CrossRefPubMed
35.
Lööv C, Shevchenko G, Nadadhur AG, Clausen F, Hillered L, Wetterhall M et al. Identification of injury specific proteins in a cell culture model of traumatic brain injury. PLoS One. 2013;8(2).
36.
Ahmed F, Gyorgy A, Kamnaksh A, Ling G, Tong L, Parks S, et al. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis. 2012;33(24):3705–11.CrossRefPubMed
37.
Kobeissy FH, Sadasivan S, Liu J, Gold MS, Wang KK. Psychiatric research: psychoproteomics, degradomics and systems biology. Expert Rev Proteomics. 2008;5(2):293–314.CrossRefPubMed
38.
Wu P, Zhao Y, Haidacher SJ, Wang E, Parsley MO, Gao J, et al. Detection of structural and metabolic changes in traumatically injured hippocampus by quantitative differential proteomics. J Neurotrauma. 2013;30(9):775–88.CrossRefPubMedPubMedCentral
39.
Alder J, Fujioka W, Lifshitz J, Crockett DP, Thakker-Varia S. Lateral fluid percussion: model of traumatic brain injury in mice. J Vis Exp. 2011;(54).
40.
Reed TT, Jr WMP, Turner DM, Markesbery WR, Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer’s disease inferior parietal lobule. J Cell Mol Med. 2009;13(8b):2019–29.CrossRefPubMed
41.
Guingab-Cagmat JD, Newsom K, Vakulenko A, Cagmat EB, Kobeissy FH, Zoltewicz S, et al. In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system. Electrophoresis. 2012;33(24):3786–97.CrossRefPubMed
42.
Liu MC, Akle V, Zheng W, Dave JR, Tortella FC, Hayes RL, et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J. 2006;394(3):715–25.CrossRefPubMedPubMedCentral
43.
Gyorgy AB, Walker J, Wingo D, Eidelman O, Pollard HB, Molnar A, et al. Reverse phase protein microarray technology in traumatic brain injury. J Neurosci Methods. 2010;192(1):96–101.CrossRefPubMed
44.
Ding Q, Wu Z, Guo Y, Zhao C, Jia Y, Kong F, et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics. 2006;6(2):505–18.CrossRefPubMed
45.
Kang S, So H, Moon Y, Kim C. Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics. 2006;6(9):2797–812.CrossRefPubMed
46.
Tsai M, Shen L, Kuo H, Cheng H, Chak K. Involvement of acidic fibroblast growth factor in spinal cord injury repair processes revealed by a proteomics approach. Mol Cell Proteomics. 2008;7(9):1668–87.CrossRefPubMedPubMedCentral
47.
Yan X, Liu J, Luo Z, Ding Q, Mao X, Yan M, et al. Proteomic profiling of proteins in rat spinal cord induced by contusion injury. Neurochem Int. 2010;56(8):971–83.CrossRefPubMed
48.
Liu W, Shang F, Xu Y, Belegu V, Xia L, Zhao W, et al. eIF5A1/RhoGDIα pathway: a novel therapeutic target for treatment of spinal cord injury identified by a proteomics approach. Sci Rep. 2015;5:16911.CrossRefPubMedPubMedCentral
49.
Chen A, Sun S, Ravikumar R, Visavadiya N, Springer J. Differential proteomic analysis of acute contusive spinal cord injury in rats using iTRAQ reagent labeling and LC–MS/MS. Neurochem Res. 2013;38(11):2247–55.CrossRefPubMed
50.
Moghieb A, Bramlett H, Das J, Yang Z, Selig T, Yost R, et al. Differential neuroproteomic and systems biology analysis of spinal cord injury. Mol Cell Proteomics. 2016;15(7):2379–95.
51.
Devaux S, Cizkova D, Quanico J, Franck J, Nataf S, Pays L et al. Proteomic analysis of the spatio-temporal based molecular kinetics of acute spinal cord injury identifies a time- and segment-specific window for effective tissue repair. Mol Cell Proteomics. 2016;15(8):2641–70.
52.
53.
Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988;60(20):2299–301.CrossRefPubMed
54.
Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yoshida T, et al. Protein and polymer analyses up tom/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 1988;2(8):151–3.CrossRef
55.
Andersson M, Groseclose M, Deutch A, Caprioli R. Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Methods. 2008;5(1):101–8.CrossRefPubMed
56.
Mainini V, Bovo G, Chinello C, Gianazza E, Grasso M, Cattoretti G, et al. Detection of high molecular weight proteins by MALDI imaging mass spectrometry. Mol Biosyst. 2013;9(6):1101–7.CrossRefPubMed
57.
Clemis E, Smith D, Camenzind A, Danell R, Parker C, Borchers C. Quantitation of spatially-localized proteins in tissue samples using MALDI-MRM imaging. Anal Chem. 2012;84(8):3514–22.CrossRefPubMed
58.
Franck J, Arafah K, Elayed M, Bonnel D, Vergara D, Jacquet A, et al. Maldi imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics. 2009;8(9):2023–33.CrossRefPubMedPubMedCentral
59.
Norris J, Caprioli R. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev. 2013;113(4):2309–42.CrossRefPubMedPubMedCentral
60.
Amstalden van Hove E, Smith D, Heeren R. A concise review of mass spectrometry imaging. J Chromatogr A. 2010;1217(25):3946–54.CrossRefPubMed
61.
Sugiura Y, Shimma S, Setou M. Two-step matrix application technique to improve ionization efficiency for matrix-assisted laser desorption/ionization in imaging mass spectrometry. Anal Chem. 2006;78(24):8227–35.CrossRefPubMed
62.
Chaurand P, Caprioli R. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis. 2002;23(18):3125–35.CrossRefPubMed
63.
Groseclose MR, Andersson M, Hardesty WM, Caprioli RM. Identification of proteins directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. J Mass Spectrom. 2007;42(2):254–62.CrossRefPubMed
64.
65.
Taverna D, Norris JL, Caprioli RM. Histology-directed microwave assisted enzymatic protein digestion for MALDI MS analysis of mammalian tissue. Anal Chem. 2015;87(1):670–6.CrossRefPubMed
66.
67.
Ceuppens R, Dumont D, Brussel LV, Plas BVD, Daniels R, Noben J-P, et al. Direct profiling of myelinated and demyelinated regions in mouse brain by imaging mass spectrometry. Int J Mass Spectrom. 2007;260(2–3):185–94.CrossRef
68.
Crecelius AC, Cornett DS, Caprioli RM, Williams B, Dawant BM, Bodenheimer B. Three-dimensional visualization of protein expression in mouse brain structures using imaging mass spectrometry. J Am Soc Mass Spectrom. 2005;16(7):1093–9.CrossRefPubMed
69.
Roux A, Muller L, Jackson SN, Post J, Baldwin K, Hoffer B, et al. Mass spectrometry imaging of rat brain lipid profile changes over time following traumatic brain injury. J Neurosci Methods. 2016;272:19–32.CrossRefPubMed
70.
Woods AS, Colsch B, Jackson SN, Post J, Baldwin K, Roux A, et al. Gangliosides and ceramides change in a mouse model of blast induced traumatic brain injury. ACS Chem Neurosci. 2013;4(4):594–600.
71.
Caughlin S, Hepburn JD, Park DH, Jurcic K, Yeung KK-C, Cechetto DF et al. Increased expression of simple ganglioside species GM2 and GM3 detected by MALDI imaging mass spectrometry in a combined rat model of Aβ toxicity and stroke. PLoS One. 2015;10(6).
72.
Whitehead SN, Chan KHN, Gangaraju S, Slinn J, Li J, Hou ST. Imaging mass spectrometry detection of gangliosides species in the mouse brain following transient focal cerebral ischemia and long-term recovery. PLoS One. 2011;6(6).
73.
Aichler M, Walch A. MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95(4):422–31.CrossRefPubMed
74.
Grant S. Systems biology in neuroscience: bridging genes to cognition. Curr Opin Neurobiol. 2003;13(5):577–82.CrossRefPubMed
75.
76.
Li C, Chen L, Aihara K. A systems biology perspective on signal processing in genetic network motifs [life sciences]. IEEE Signal Process Mag. 2007;24(2):136–47.CrossRef
77.
Choudhary J, Grant SGN. Proteomics in postgenomic neuroscience: the end of the beginning. Nat Neurosci. 2004;7(5):440–5.CrossRefPubMed
78.
Beltrao P, Kiel C, Serrano L. Structures in systems biology. Curr Opin Struct Biol. 2007;17(3):378–84.CrossRefPubMed
79.
Feala JD, Abdulhameed MDM, Yu C, Dutta B, Yu X, Schmid K, et al. Systems biology approaches for discovering biomarkers for traumatic brain injury. J Neurotrauma. 2013;30(13):1101–16.CrossRefPubMedPubMedCentral
80.
Didangelos A, Puglia M, Iberl M, Sanchez-Bellot C, Roschitzki B, Bradbury E. High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury. Sci Rep. 2016;6:21607.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Application of Proteomics to Traumatic Brain and Spinal Cord Injuries
verfasst von
George Anis Sarkis
Manasi D. Mangaonkar
Ahmed Moghieb
Brian Lelling
Michael Guertin
Hamad Yadikar
Zhihui Yang
Firas Kobeissy
Kevin K. W. Wang
Publikationsdatum
01.03.2017
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 3/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0736-z

Weitere Artikel der Ausgabe 3/2017

Current Neurology and Neuroscience Reports 3/2017 Zur Ausgabe

Genetics (V Bonifati, Section Editor)

Update on the Genetics of Dystonia

Headache (RB Halker, Section Editor)

Recurrent Gastrointestinal Disturbance: Abdominal Migraine and Cyclic Vomiting Syndrome

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurological and Neurosurgical Emergencies in Patients with Hematological Disorders

Neuroimaging (DJ Brooks, Section Editor)

Neuroinflammation in Neurodegenerative Disorders—a Review

Headache (RB Halker, Section Editor)

Migraine and Stroke: What’s the Link? What to Do?

Headache (RB Halker, Section Editor)

PFO and Migraine: Is There a Role for Closure?

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise